Efficacy and safety of ombitasvir/paritaprevir/ritonavir and ribavirin for chronic hepatitis patients infected with genotype 2a in Japan-Reference-Cited by-同舟云学术

Efficacy and safety of ombitasvir/paritaprevir/ritonavir and ribavirin for chronic hepatitis patients infected with genotype 2a in Japan

Published:2019-01-02 Issue:4 Volume:49 Page:369-376
ISSN:1386-6346
Container-title:Hepatology Research
language:en
Short-container-title:Hepatol Res

Author:

Atsukawa Masanori¹,Tsubota Akihito²,Toyoda Hidenori³^ORCID,Takaguchi Koichi⁴,Nakamuta Makoto⁵,Watanabe Tsunamasa⁶,Tada Toshifumi³^ORCID,Tsutsui Akemi⁴,Ikeda Hiroki⁶,Abe Hiroshi⁷,Kato Keizo⁷,Uojima Haruki⁸,Ikegami Tadashi⁹,Asano Toru¹⁰,Kondo Chisa¹,Koeda Mai¹¹,Okubo Tomomi¹¹,Arai Taeang¹¹,Iwashita‐Nakagawa Ai¹¹,Itokawa Norio¹¹,Kumada Takashi³,Iwakiri Katsuhiko¹

Affiliation:

1. Division of Gastroenterology and Hepatology, Department of Internal MedicineNippon Medical School Tokyo

2. Core Research Facilities for Basic Science, Research Center for Medical SciencesJikei University School of Medicine Tokyo

3. Department of GastroenterologyOgaki Municipal Hospital Ogaki

4. Department of HepatologyKagawa Prefectural Central Hospital Takamatsu

5. Department of GastroenterologyNational Hospital Organization Kyushu Medical Center Fukuoka

6. Department of Internal MedicineSt. Marianna University School of Medicine Kawasaki

7. Department of Gastroenterology and HepatologyShinmatsudo Central General Hospital Matsudo

8. Department of Gastroenterology, Internal MedicineKitasato University School of Medicine Sagamihara

9. Department of Internal Medicine, Division of Gastroenterology HepatologyTokyo Medical University Ibaraki Medical Center Ibaraki

10. Department of Internal Medicine, Division of Gastroenterology and HepatologyTokyo Metropolitan Bokutoh Hospital Tokyo

11. Department of Internal Medicine, Division of GastroenterologyNippon Medical School Chiba Hokusoh Hospital Inzai Japan

Publisher

Wiley

Subject

Infectious Diseases,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hepr.13292

Reference18 articles.

1. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection

2. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial

3. Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection

4. The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study

5. The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characterisation of a Hepatitis C Virus Subtype 2a Cluster in Scottish PWID with a Suboptimal Response to Glecaprevir/Pibrentasvir Treatment;Viruses;2022-07-29

2. A novel noninvasive formula for predicting cirrhosis in patients with chronic hepatitis C;PLOS ONE;2021-09-10

3. Real‐world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1‐ and 2‐infected patients with decompensated cirrhosis: A nationwide multicenter study by the Japanese Red Cross Liver Study Group;Journal of Medical Virology;2021-07-03

4. Effect of Direct-Acting Antiviral Therapy on Thrombocytopenic Patients with Hepatitis C Virus-Related Chronic Liver Disease;Gastroenterology Research and Practice;2021-05-23

5. Effectiveness and safety of ombitasvir/paritaprevir/ritonavir in treatment of chronic hepatitis C Egyptian hemodialysis patients, case-control study;Egyptian Liver Journal;2021-01-27